Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13837758 | 0.84 | GSK3A (0.45) | KDM4EALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL16137958 | 0.83 | HDAC6 (0.53) | KDM4EPSMB5ALDH1A1KMT2AMCL1 | |
| SCHEMBL9609771 | 0.82 | KAT2B (0.43) | KAT2BKDM4EPSMB5SMN1; SMN2GAA | |
| SCHEMBL17512273 | 0.80 | HDAC6 (0.45) | KDM4EPSMB5ALDH1A1MEN1KMT2A | |
| SCHEMBL15469110 | 0.78 | MAPT (0.43) | KAT2BKDM4EPSMB5SMN1; SMN2GAA | |
| SCHEMBL24803269 | 0.77 | GRIN2B (0.42) | KMT2A | |
| SCHEMBL21810438 | 0.77 | KDM4E (0.48) | CASP3KDM4EPSMB5SMN1; SMN2ALDH1A1 | |
| SCHEMBL21810428 | 0.77 | NTSR1 (0.57) | CASP3PSMB5ATM | |
| SCHEMBL21218000 | 0.77 | SMN1; SMN2 (0.51) | KDM4EPSMB5SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL13552201 | 0.77 | CES1 (0.47) | PSMB5GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9809545-B2 | Factor XIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809545-B2 | Factor XIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809545-B2 | Factor XIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-11-07 | — | — | US | disclosed |
| EP-2978425-B1 | FACTOR XIA INHIBITORS | MERCK SHARP & DOHME (US) | 2017-09-27 | — | — | EP | disclosed |
| US-20160046581-A1 | Factor XIa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160046581-A1 | Factor XIa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160046581-A1 | Factor XIa Inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-02-18 | — | — | US | disclosed |
| WO-2014160592-A2 | FACTOR XIa INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046581-A1 | Factor XIa Inhibitors | F11, F12, TFPI | CASP3 1374/4885KAT2B 1214/4885KDM4E 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.